MyoKardia, Inc.

( )
MYOK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
HZNPHorizon Therapeutics Plc -1.29%58.006.5%$170.71m
CTLTCatalent, Inc. 3.87%79.172.1%$133.07m
VRXValeant Pharmaceuticals International, Inc. -2.28%17.1514.1%$100.91m
JAZZJazz Pharmaceuticals Plc -1.93%105.462.4%$84.71m
BHCBausch Health Cos., Inc. -2.28%17.150.0%$70.94m
UTHRUnited Therapeutics Corp. -0.73%116.9214.3%$69.38m
ICPTIntercept Pharmaceuticals, Inc. -0.43%43.8616.8%$61.18m
PCRXPacira Biosciences, Inc. 1.73%57.5210.3%$54.94m
AXSMAxsome Therapeutics, Inc. -4.57%81.922.1%$51.49m
ZGNXZogenix, Inc. -1.66%27.817.5%$48.46m
PRGOPerrigo Co. Plc -1.20%54.276.8%$47.19m
MYOKMyoKardia, Inc. -2.27%93.131.8%$45.55m
ARGXargenx SE 0.70%253.130.0%$43.15m
GWPHGW Pharmaceuticals Plc -0.69%128.116.2%$38.78m
ICLRICON plc 1.68%174.284.3%$38.34m

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.